Welcome to our dedicated page for Nervgen Pharma SEC filings (Ticker: NGENF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NervGen Pharma Corp. (NGENF) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer, including documents filed under the Multijurisdictional Disclosure System (MJDS). NervGen has filed a registration statement on Form F-10 with the U.S. Securities and Exchange Commission (SEC), and its Form 6-K reports, such as the current report dated January 8, 2026, reference this registration statement and incorporate certain materials by reference.
Through these filings, investors can review detailed information about NervGen’s business as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The filings may include descriptions of the company’s lead candidate NVG-291, its Phase 1b/2a CONNECT SCI Study, preclinical work with NVG-291-R, and the broader development strategy. They also provide insight into capital-raising activities, such as non-brokered private placements and at-the-market equity programs, and into the company’s use of the MJDS framework for cross-border offerings.
On Stock Titan, NervGen’s SEC filings are updated in near real time as new documents become available on EDGAR, including Forms 6-K and the Form F-10 registration statement. AI-powered summaries help explain the key points of lengthy filings, highlighting items such as risk factor discussions, clinical program descriptions, and financing terms in more accessible language. Users can quickly locate annual and other continuous disclosure documents filed with the SEC and see how they relate to NervGen’s clinical and corporate milestones.
For investors analyzing NGENF, this page offers a structured view of NervGen’s U.S. regulatory record, with tools to navigate complex filings and understand how the company presents its neuroreparative programs, financial position, and capital markets activities to regulators and the market.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.
Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.
NervGen Pharma Corp. has appointed Dr. Adam Rogers as its Chief Executive Officer and President, effective immediately, after he served as interim CEO and Board Chair. He will continue as Chairperson of the Board.
Under his new employment agreement with a U.S. subsidiary, Dr. Rogers will receive a $350,000 annual base salary and be eligible for an annual bonus of up to 30% of salary. He was granted options to purchase 717,891 common shares, split between options priced at $5.06 and $5.57 per share, vesting over four years. The Board also agreed to grant an additional 1,146,108 performance-based options, plus 37,784 fully vested shares and 617,135 performance-based restricted stock units, subject to equity plan approvals.
The agreement includes severance and change-of-control protections, providing salary continuation, COBRA benefits, bonus eligibility and equity vesting acceleration in certain terminations, with enhanced vesting if a qualifying termination occurs around a change of control.
NervGen Pharma Corp. submitted a Form 6-K as a foreign private issuer for January 2026. The company confirms it files annual reports under Form 40-F, which is the standard for certain Canadian issuers.
Exhibit 99.1, a Material Change Report dated January 8, 2026, is included with this submission and is incorporated by reference into NervGen’s Form F-10 registration statement (File No. 333-292197). The report is signed on behalf of the company by Chief Financial Officer William J. Adams.
NervGen Pharma Corp. has filed Amendment No. 1 to a Form F-10 registration statement linked to an amended and restated Canadian short form base shelf prospectus covering up to U.S.$150,000,000 of securities. Over a 25‑month period, the company and certain securityholders may sell common shares, debt securities, subscription receipts, warrants and units in various combinations, including potential at‑the‑market distributions, with exact terms set in future prospectus supplements. NervGen is a clinical‑stage biopharmaceutical company developing neuroreparative therapies, led by NVG‑291 for spinal cord injury, and currently has no approved products or product revenue. The prospectus notes plans to list common shares on the Nasdaq Capital Market under the symbol “NGEN”, while they remain listed on the TSX‑V and OTCQB. Extensive risk disclosures highlight ongoing losses, the need for additional capital, clinical and regulatory uncertainty, and cross‑border enforcement and disclosure differences for U.S. investors.